ENT1 Antibody (C-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP1086b
Background:
ENT1 is a member of the equilibrative nucleoside transporter family. It is a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative (as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies.
Other Names:
Equilibrative nucleoside transporter 1, Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter, Equilibrative NBMPR-sensitive nucleoside transporter, Nucleoside transporter, es-type, Solute carrier family 29 member 1, SLC29A1, ENT1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1086b was selected from the C-term region of human ENT1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: SLC29A1 (HGNC:11003)
Gene ID: 2030
Primary Accession: Q99808
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
ENT1 is a member of the equilibrative nucleoside transporter family. It is a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative (as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies.
Other Names:
Equilibrative nucleoside transporter 1, Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter, Equilibrative NBMPR-sensitive nucleoside transporter, Nucleoside transporter, es-type, Solute carrier family 29 member 1, SLC29A1, ENT1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1086b was selected from the C-term region of human ENT1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: SLC29A1 (HGNC:11003)
Gene ID: 2030
Primary Accession: Q99808
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review